Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer.
Seda KahramanEnes ErulMustafa SeyyarOzge GumusayErtugrul BayramBurcin Cakan DemirelOmer AcarSercan AksoyNaziyet Kose BaytemurElif SahinDevrim CabukGul BasaranSemra PaydaşArzu YarenDeniz Can GuvenAtike Pinar ErdoganUmut DemirciAlper Yasarİbrahim Vedat BayogluMutlu HizalBurcu GulbagciNail PaksoySena Ece DavarciFunda YilmazOzlem DoganSibel Oyucu OrhanErkan KayıkçıoğluAli AytacMerve KeskinkilicEda Eylemer MocanOlcun Umit UnalEsra AydinHakan YucelDeniz IsikOnder ErenBasak Oyan UlucMelike OzcelikIlhan HacibekirogluAdnan AydinerHacer DemirBerna OksuzogluEbru CilbirErdem CubukcuBulent CetinEsin OktayCihan ErolSadi Kerem OkuturNilgun YildirimAli AlkanFatih SelcukbiricikAsude AksoyYusuf KarakasGulhan OzkanliBerna Bozkurt DumanDincer AydinOzgecan DulgarMuhammed Muhiddin ErFatih TekerTugba YavuzsenMusa Baris AykanAli InalYakup IriagacNurhan Onal KalkanMurat KeserTeoman SakalarSerkan MenekseEngin KutBurak BilginMuge KaraoglanogluVeli SunarOzlem OzdemirNazim Serdar TurhalNuri KaradurmusBulent YalcinMehmet Ali Nahit SendurPublished in: Future oncology (London, England) (2023)
Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference.
Keyphrases
- metastatic breast cancer
- estrogen receptor
- free survival
- polycystic ovary syndrome
- healthcare
- early breast cancer
- palliative care
- insulin resistance
- type diabetes
- binding protein
- quality improvement
- cell cycle
- pain management
- big data
- metabolic syndrome
- chronic pain
- adipose tissue
- case report
- electronic health record
- newly diagnosed
- replacement therapy